Aligos Therapeutics Inc.

NASDAQ: ALGS · Real-Time Price · USD
7.69
0.11 (1.38%)
At close: Aug 15, 2025, 12:52 PM

Aligos Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-131.21M -87.68M -96.05M -128.33M
Depreciation & Amortization
2.62M 3.07M 3.67M 3.78M
Stock-Based Compensation
8.45M 12.65M 14.69M 13.46M
Other Working Capital
-5.01M -7.31M -3.27M -4.34M
Other Non-Cash Items
44.35M 2.49M -159K 86K
Deferred Income Tax
n/a n/a n/a n/a
Change in Working Capital
-4.96M -9.53M -1.55M -4.65M
Operating Cash Flow
-80.74M -79M -79.39M -115.66M
Capital Expenditures
-130K -19K -943K -892K
Cash Acquisitions
n/a n/a 25.35M -3.91M
Purchase of Investments
-108.15M -11K -104.27M -19.09M
Sales Maturities Of Investments
90M 45.01M 78.92M 23M
Other Investing Acitivies
n/a n/a -25.35M 3.91M
Investing Cash Flow
-18.28M 44.98M -26.29M 3.02M
Debt Repayment
-83K -96K -61K -79K
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
438K 70.98M 225K 172K
Financial Cash Flow
355K 88.33M 164K 78.68M
Net Cash Flow
-98.67M 54.31M -105.52M -33.96M
Free Cash Flow
-80.87M -79.02M -80.33M -116.55M